Evidence map›Paper›PMID 24653633›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone.

Yongxiang Yi, Yufeng Zhang, Qiang Wei, Liang Zhao, Jianbo Han, Yan Song, Ying Ding, Guilan Lu, Junmao Liu, Huaiying Ding and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yongxiang Yi1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Yufeng Zhang1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Qiang Wei1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Liang Zhao1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Jianbo Han1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Yan Song1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Ying Ding1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Guilan Lu1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Junmao Liu1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Huaiying Ding1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Feng Dai1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Xiaojun Tang1 Department of Hepatobiliary Surgery; 2 Department of Medical Imaging, the Second Affiliated Hospital of Southeast University, Nanjing 210003, China.
Second Affiliated Hospital of Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare radiofrequency ablation (RFA) or microwave ablation (MWA) and transcatheter arterial chemoembolization (TACE) with RFA or MWA monotherapy in hepatocellular carcinoma (HCC).

methodsA prospective, randomized, controlled trial was conducted on 94 patients with HCC ≤7 cm at a single tertiary referral center from June 2008 to June 2010 at the Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Southeast University. The patients were randomly assigned into the TACE-RFA or TACE-MWA (combined treatment group) and the RFA-alone or MWA-alone groups (control group). The primary end point was overall survival. The secondary end point was recurrence-free survival, and the tertiary end point was adverse effects.

resultsUntil the time of censor, 17 patients in the TACE-RFA or TACE-MWA group had died. The median follow-up time of the patients who were still alive for the TACE-RFA or TACE-MWA group was 47.5±11.3 months (range, 29 to 62 months). The 1-, 3- and 5-year overall survival for the TACE-RFA or TACE-MWA group was 93.6%, 68.1% and 61.7%, respectively. Twenty-five patients in the RFA or MWA group had died. The median follow-up time of the patients who were still alive for the RFA or MWA group was 47.0±12.9 months (range, 28 to 62 months). The 1-, 3- and 5-year overall survival for the RFA or MWA group was 85.1%, 59.6% and 44.7%, respectively. The patients in the TACE-RFA or TACE-MWA group had better overall survival than the RFA or MWA group [hazard ratio (HR), 0.526; 95% confidence interval (95% CI), 0.334-0.823; P=0.002], and showed better recurrence-free survival than the RFA or MWA group (HR, 0.582; 95% CI, 0.368-0.895; P=0.008).

conclusionsRFA or MWA combined with TACE in the treatment of HCC ≤7 cm was superior to RFA or MWA alone in improving survival by reducing arterial and portal blood flow due to TACE with iodized oil before RFA.

Indexed as

hepatocellular carcinoma (HCC)Radiofrequency ablation (RFA)transcatheter arterial chemoembolization (TACE)

Identifiers

PMID24653633
PMCPMC3937757
OpenAlexW23242163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.